Table 2.

Risk of HR-negative or positive breast cancer associated with statin use

HR-negative cases N = 3,669Matched controlsaN = 36,690HR-positive cases N = 17,195Matched controlscN = 171,950
Statin usen (col%)n (col%)OR [95% confidence interval (CI)]bn (col%)n (col%)OR (95% CI)d
Never3,147 (85.8)31,474 (85.8)Reference14,317 (83.3)143,063 (83.2)Reference
≥2 years257 (7.0)2,720 (7.4)0.93 (0.81–1.08)1,593 (9.3)15,623 (9.1)1.02 (0.96–1.08)
Never3,147 (85.8)31,474 (85.8)Reference14,317 (83.3)143,063 (83.2)Reference
<1 y132 (3.6)1,257 (3.4)1.04 (0.87–1.25)654 (3.8)6,808 (4.0)0.95 (0.88–1.04)
≥1–2 y133 (3.6)1,239 (3.4)1.07 (0.88–1.28)631 (3.7)6,456 (3.7)0.97 (0.89–1.06)
≥2–3 y91 (2.5)829 (2.3)1.09 (0.87–1.36)465 (2.7)4,717 (2.7)0.98 (0.89–1.08)
≥3–5 y96 (2.6)1,063 (2.9)0.89 (0.72–1.11)593 (3.4)5,990 (3.5)0.99 (0.90–1.08)
≥5 y70 (1.9)828 (2.3)0.83 (0.65–1.08)535 (3.1)4,916 (2.9)1.08 (0.98–1.19)
  • aControls matched to HR-negative cases bases on age at diagnosis/index date and years of prescription drug coverage.

  • bORs based on conditional logistic regression among HR-negative cases and their matched controls, adjusted for oral contraceptive and hormone therapy use.

  • cControls matched to HR-positive cases bases on age at diagnosis/index date and years of prescription drug coverage.

  • dORs based on conditional logistic regression among HR-positive cases and their matched controls, adjusted for oral contraceptive and hormone therapy use.